Cochrane Review: Prostacyclin for pulmonary arterial hypertension

Zusammenfassung

Prostacyclin zur Behandlung der pulmonalen Hypertonie - Barnes, H - 2019 \| Cochrane Library [Skip to Content](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012785.pub2/full/de#main-content) [Close cookies message](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012785.pub2/full/de#) Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish

Kerninformationen

](https://www.cochranelibrary.com/en/about/about-cochrane-reviews) Review - Intervention Collapse all Expand all ## Abstract available in ### Background Pulmonary arterial hypertension (PAH) is characterised by pulmonary vascular changes, leads to elevated pulmonary artery pressures, dyspnoea,...

sk of adverse events. Newer and safer subcutaneous, oral and inhaled preparations are now available, though possibly less potent. Selexipag is an oral selective prostacyclin receptor (IP receptor) agonist that works similarly to prostacyclin, potentially more stable, with less complex administratio...

nalogues or prostacyclin receptor agonists to control (placebo, any other treatment or usual care) for at least six weeks. ### Data collection and analysis We used standard methods specified by Cochrane. Primary outcomes included change in World Health Organization (WHO) functional class, six‐minu...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen